Race, tumor location, and disease progression among low-risk prostate cancer patients.
Adult
Black or African American
/ statistics & numerical data
Aged
Biopsy
Disease Progression
Disease-Free Survival
Follow-Up Studies
Humans
Kallikreins
/ blood
Kaplan-Meier Estimate
Male
Middle Aged
Neoplasm Recurrence, Local
/ blood
Prognosis
Proportional Hazards Models
Prostate
/ pathology
Prostate-Specific Antigen
/ blood
Prostatectomy
Prostatic Neoplasms
/ blood
Retrospective Studies
Risk Assessment
/ methods
United States
/ epidemiology
White People
/ statistics & numerical data
general surgery
prostatic neoplasms
race factors
risk
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
03 2020
03 2020
Historique:
received:
11
12
2019
revised:
06
01
2020
accepted:
06
01
2020
pubmed:
23
1
2020
medline:
24
4
2021
entrez:
23
1
2020
Statut:
ppublish
Résumé
The relationship between race, prostate tumor location, and BCR-free survival is inconclusive. This study examined the independent and joint roles of patient race and tumor location on biochemical recurrence-free (BCR) survival. A retrospective cohort study was conducted among men with newly diagnosed, biopsy-confirmed, NCCN-defined low risk CaP who underwent radical prostatectomy (RP) at the Walter Reed National Military Medical Center from 1996 to 2008. BCR-free survival was modeled using Kaplan-Meier estimation curves and multivariable Cox proportional hazards (PH) analyses. There were 539 eligible patients with low-risk CaP (25% African American, AA; 75% Caucasian American, CA). Median age at CaP diagnosis and post-RP follow-up time was 59.2 and 8.1 years, respectively. Kaplan-Meier analyses showed no significant association between race (P = .52) or predominant tumor location (P = .98) on BCR-free survival. In Cox PH multivariable analysis, neither race (HR = 1.18; 95% CI = 0.68-2.02; P = .56) nor predominant tumor location (HR = 1.13; 95% CI = 0.59-2.15; P = .71) was an independent predictor of BCR-free survival. Neither race nor predominant tumor location was associated with adverse oncologic outcome.
Sections du résumé
BACKGROUND
The relationship between race, prostate tumor location, and BCR-free survival is inconclusive. This study examined the independent and joint roles of patient race and tumor location on biochemical recurrence-free (BCR) survival.
METHODS
A retrospective cohort study was conducted among men with newly diagnosed, biopsy-confirmed, NCCN-defined low risk CaP who underwent radical prostatectomy (RP) at the Walter Reed National Military Medical Center from 1996 to 2008. BCR-free survival was modeled using Kaplan-Meier estimation curves and multivariable Cox proportional hazards (PH) analyses.
RESULTS
There were 539 eligible patients with low-risk CaP (25% African American, AA; 75% Caucasian American, CA). Median age at CaP diagnosis and post-RP follow-up time was 59.2 and 8.1 years, respectively. Kaplan-Meier analyses showed no significant association between race (P = .52) or predominant tumor location (P = .98) on BCR-free survival. In Cox PH multivariable analysis, neither race (HR = 1.18; 95% CI = 0.68-2.02; P = .56) nor predominant tumor location (HR = 1.13; 95% CI = 0.59-2.15; P = .71) was an independent predictor of BCR-free survival.
CONCLUSIONS
Neither race nor predominant tumor location was associated with adverse oncologic outcome.
Identifiants
pubmed: 31965751
doi: 10.1002/cam4.2864
pmc: PMC7064097
doi:
Substances chimiques
KLK3 protein, human
EC 3.4.21.-
Kallikreins
EC 3.4.21.-
Prostate-Specific Antigen
EC 3.4.21.77
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2235-2242Informations de copyright
© 2020 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
J Urol. 2007 Feb;177(2):540-5
pubmed: 17222629
Eur Urol. 2016 Jul;70(1):14-17
pubmed: 26443432
Cancer. 2017 Nov 1;123(21):4199-4206
pubmed: 28654204
Prostate Cancer Prostatic Dis. 2014 Mar;17(1):75-80
pubmed: 24296774
Urol Oncol. 2009 Sep-Oct;27(5):562-9
pubmed: 19720304
Urology. 2012 Sep;80(3):661-6
pubmed: 22925240
Cancer Med. 2020 Mar;9(6):2235-2242
pubmed: 31965751
BJU Int. 2017 Nov;120(5):651-658
pubmed: 28371244
CA Cancer J Clin. 2017 Jan;67(1):7-30
pubmed: 28055103
Prostate. 1981;2(1):35-49
pubmed: 7279811
Oncotarget. 2018 Apr 20;9(30):21359-21365
pubmed: 29765545
Am J Surg Pathol. 2016 Feb;40(2):244-52
pubmed: 26492179
BJU Int. 2006 Dec;98(6):1167-71
pubmed: 17026586
Urology. 2014 Dec;84(6):1434-41
pubmed: 25432835
Int Urol Nephrol. 2014 Oct;46(10):1941-6
pubmed: 24969031
JAMA Oncol. 2019 Jul 1;5(7):975-983
pubmed: 31120534
JAMA. 1994 Feb 2;271(5):368-74
pubmed: 7506797
Prostate. 1998 Dec 1;37(4):230-5
pubmed: 9831219
Mod Pathol. 2008 Feb;21(2):67-75
pubmed: 18065961
J Urol. 2016 Nov;196(5):1408-1414
pubmed: 27352635